Gansu province is a high incidence area of gastric cancer, and the mortality caused by gastric cancer ranks first in China. A safe and effective treatment of gastric cancer is the key point in the research. In recent years, tumor targeted therapy has become a new research direction along with the gradually increased understanding of the molecular biology of cancer mechanism. Several studies have shown that increased expression of cyclooxygenase (COX)－2 plays an important role in the occurrence and development of malignant tumor. Celecoxib, a non steroidal anti inflammatory drug, is a novel COX－2 selective inhibitor which can significantly reduce the incidence of gastrointestinal malignancy, and inhibit tumorigenesis through inhibiting tumor growth and tumor angiogenesis, inducing the apoptosis of tumor cells, reversing multidrug resistance, enhancing the cytotoxicity and radiosensitivity of chemotherapy drugs, and producing synergistic effects with combining chemotherapy and radiotherapy. Therefore, celecoxib has the potential to be the treatment of choice for gastric cancer.
DownLoad: